VolitionRx Limited (VNRX) Q3 2026 earnings review
Volition cuts its losses and debt, but cash stays tight
Volition, which develops blood tests for cancer and sepsis, narrowed its losses and paid off its debt while waiting for a major commercial deal. Third-quarter operating loss fell 35% to $3.3 million as chief executive Cameron Reynolds cut staff by 28% and recognized $1.6 million in revenue. The company raised $5.2 million from stock sales and paid off its $7.5 million convertible note, leaving $2.4 million in cash.
| Revenue | $1.6M +157% from a year ago, on deferred revenue |
|---|---|
| Operating loss | $3.3M down 35% from $5.1M a year ago |
| Cash on hand | $2.4M after paying off $7.5M convertible note |
| Cat study & lung filing plan | Unchanged both targeted for the fourth quarter |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower expenses and a debt-free balance sheet are offset by a tight cash runway and unsigned partnerships. Paying off the convertible note removes future debt-related dilution, and clinical studies in France and with distributor Missionpharma are advancing. One caution: the revenue jump came from accounting recognition of past partner payments rather than new cash sales, and Reynolds cut his salary in half until a large licensing deal closes.
The question now is whether non-dilutive cash arrives before Volition has to sell more stock. Either the company unlocks its $5 million veterinary milestone and signs a human licensing deal in the fourth quarter, or it relies on further share sales to cover its quarterly losses. Publication of the cat lymphoma paper and a signed partner contract this quarter will tell.
🐂 Bull Case
Staff Cuts Lowered the Operating Loss by a Third
Volition, a developer of blood tests for cancer and sepsis, has spent the past year shrinking its research spending to focus on selling its tests. Because revenue is still small, cutting day-to-day overhead is the fastest way management can stretch its cash while it negotiates with larger diagnostic companies.
Operating expenses fell 14% from a year ago, driven by an ongoing cost-reduction programme "including a 28% reduction in headcount compared to the same point last year", the company said. Combined with higher recognized revenue, those savings narrowed the third-quarter operating loss by 35% to $3.3 million, down from $5.1 million a year earlier and $4.2 million in the second quarter.
What to watch: fourth-quarter operating expenses in the full-year report. A further drop will show how much extra cash the November executive and board pay cuts save each quarter.
Prepaying the $7.5 Million Convertible Note Removed Debt
Early-stage medical test makers often rely on convertible notes, which are loans that can turn into stock and dilute shareholders. In the third quarter, Volition paid off the entire remaining balance of its $7.5 million convertible note in cash, removing that debt overhang from its balance sheet.
Clearing the note stops future stock dilution from debt conversions and eliminates related charges, which added $0.4 million in non-cash costs to this quarter's net loss. What to watch: the debt schedule in the third-quarter filing, which will confirm whether any other loan obligations remain.
Sepsis and Cancer Tests Reached Hospital Studies
Volition wants large healthcare companies to license its Nu.Q blood-test platform and Capture-Seq, its method for isolating tumour DNA from blood. In September, the group joined the launch of DETECSEPS, a €6.3 million French government programme "evaluating our automated Nu.Q ® NETs assay as the sole biomarker for early detection of sepsis in hospital emergency departments", chief executive Cameron Reynolds said.
The diagnostics developer also signed an October letter of intent with distributor Missionpharma to test a rapid finger-prick sepsis prototype for newborns in lower-income countries. Following an August study publication for Capture-Seq, Reynolds is in licensing talks "to target Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) opportunities". What to watch: a binding distribution contract with Missionpharma, which would turn the October letter into commercial orders.
🐻 Bear Case
Cash Covers Less Than One Quarter of Losses
Reynolds said Volition took action to strengthen its financial profile by cutting costs and paying down debt. Yet after spending $7.5 million in cash to pay off its convertible note and raising $5.2 million from stock sales, the company ended September with $2.4 million in cash, up from $1.1 million at the end of 2025.
- Cash on hand at September 30: $2.4 million
- Third-quarter operating loss: $3.3 million, or 1.4 times ending cash by our math
- Cash used in debt paydown minus stock sales: $2.3 million net outflow by our math
That cash balance covers less than three months of operating losses by our math. The strain is why Reynolds cut his base salary to half its original level from November 1 "until execution of a substantial licensing agreement", and the board cut its cash fees by at least half.
What to watch: fourth-quarter stock sales or licensing upfront payments. Without an immediate deal or the $5 million veterinary payment, Volition must sell more shares to fund operations.
Revenue Growth Came From Accounting, Not New Sales
Third-quarter revenue rose 157% from a year ago to $1.6 million, up from $0.4 million in the second quarter. However, Volition said this increase came from "reflecting an increase in recognition of deferred revenue" — recording cash that a partner paid in an earlier period rather than collecting new cash from test sales today.
A similar accounting adjustment drove first-quarter revenue to $1.0 million before sales dropped back to $0.4 million in the second quarter. Because deferred-revenue adjustments bring in no new cash, they do not help pay the bills. What to watch: the revenue table in the quarterly filing, which separates product sales from deferred-revenue accounting.
Licensing Deals and Vet Milestone Remain Unsigned
Volition's plan to fund itself rests on signing upfront licensing deals with human-diagnostics companies and collecting a $5 million milestone payment for its cat cancer test. To unlock that $5 million payment, a medical journal must first publish the company's study showing the test detected 86% of feline lymphomas.
Researchers submitted that cat manuscript in May, and six months later it is still unpublished. Meanwhile, talks with more than a dozen diagnostic companies have not yet yielded a major human licensing contract. What to watch: publication of the feline study before year-end, because another delay pushes the $5 million cash payment into 2027.
👓 Other Themes
Dependent on European Hospital and Grant Timelines
Volition relies on European public healthcare agencies to fund and approve its first routine human tests. In France, government grants pay for the €6.3 million DETECSEPS emergency-room sepsis study, and national regulators decide whether to reimburse the Nu.Q lung cancer test developed with Hospices Civils de Lyon. Because public hospitals and health ministries move on their own schedules, the company cannot control when clinical adoption begins.
💲 Other KPIs
Net loss narrowed by 30% from $5.4 million a year ago, helped by lower staff costs and higher deferred-revenue recognition. The quarter's figure includes $0.4 million in non-cash charges from the convertible note that Volition paid off during the period. Excluding those charges, the loss was $3.4 million by our math.
Volition raised $5.2 million in net cash by selling shares through its at-the-market stock facility in the third quarter. That matches the $5.4 million it raised through the same facility in the first quarter, bringing total stock-sale proceeds reported across those two quarters to $10.6 million by our math.
🔮 Guidance
Unchanged. Management anticipates a medical journal will publish its cat lymphoma study in the fourth quarter, keeping the milestone inside its earlier 2026 target. Volition submitted the paper in May. Publication is a required condition to unlock a $5 million milestone payment from its veterinary partner.
Unchanged. The group expects to file for French healthcare reimbursement for its Nu.Q lung cancer test in the fourth quarter alongside partner Hospices Civils de Lyon. Approval would allow French hospitals to use and bill for the test routinely before the company expands to other countries.
❓ Key Questions
How much third-quarter revenue came from actual product sales?
Volition reported $1.6 million in revenue, driven by an increase in deferred-revenue recognition. Because accounting recognition brings in no new cash, investors need the exact split between product shipments and deferred revenue from the quarterly filing.
How soon after journal publication does the $5 million arrive?
Publishing the feline lymphoma paper is a required step to unlock a $5 million milestone payment, and management expects publication in the fourth quarter. With only $2.4 million in cash at September 30, the exact collection timeline determines near-term funding needs.
What was operating cash burn in the third quarter?
The press release reported a $3.3 million operating loss and $2.4 million in ending cash, but did not include the cash flow statement. Operating cash use was $5.2 million in the second quarter and $5.3 million in the first quarter.
How much cash remains available under the stock-sale facility?
Volition raised $5.2 million in the third quarter and $5.4 million in the first quarter by selling shares on the open market. Knowing the remaining capacity on that facility shows how the company can fund itself until a licensing deal closes.